Impact of Pre-transplant Anti-fibrotic Therapy for IPF Upon Lung Transplant Outcomes

CompletedOBSERVATIONAL
Enrollment

320

Participants

Timeline

Start Date

April 15, 2019

Primary Completion Date

December 31, 2019

Study Completion Date

March 1, 2020

Conditions
Idiopathic Pulmonary Fibrosis
Interventions
OTHER

Retrospective observational study- no intervention to occur.

Subject data will be grouped based on the anti-fibrotic medication at the time of lung transplant listing eligibility and when medication was stopped relative to the transplant.

Trial Locations (8)

19104

University of Pennsylvania, Philadelphia

19122

Temple University, Philadelphia

27705

Duke University, Durham

44195

Cleveland Clinic, Cleveland

52242

University of Iowa, Iowa City

63110

Washington University in St. Louis, St Louis

02114

Massachusetts General Hospital, Boston

02115

Brigham and Women's Hospital, Boston

Sponsors

Collaborators (1)

All Listed Sponsors
collaborator

Boehringer Ingelheim

INDUSTRY

lead

Steward St. Elizabeth's Medical Center of Boston, Inc.

OTHER

NCT04316780 - Impact of Pre-transplant Anti-fibrotic Therapy for IPF Upon Lung Transplant Outcomes | Biotech Hunter | Biotech Hunter